New hope for lung cancer: immunotherapy without chemo shows promise

NCT ID NCT05047250

Ongoing Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This phase III trial is testing the immunotherapy drug atezolizumab (Tecentriq) in 60 people with advanced non-small cell lung cancer that has high PD-L1 levels and has not been treated before. Participants receive the drug every three weeks. The study aims to see if it helps them live longer and controls the cancer, while monitoring side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Atezolizumab (Tecentriq)
What this could lead to: If successful, this could provide a new first-line treatment option for people with advanced lung cancer who have high PD-L1 levels, potentially improving survival without chemotherapy.
What could go wrong: This is a single-arm study with no comparison group, so results may be less definitive. The drug may not work for everyone and can cause immune-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma non-small cell squamous lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Anhui Province Cancer Hospital

Hefei, 230001, China
Beijing Chest Hospital

Beijing, 101149, China
Beijing Tiantan Hospital,Capital Medical University

Beijing, 100050, China
Cancer Hospital of Shantou University Medical College

Shantou, 515041, China
Daping Hospital of Third Military Medical University

Chongqing, 400042, China
Fujian Cancer Hospital

Fuzhou, 350014, China
Linyishi Cancer Hospital

Linyi, 276034, China
Nanjing Chest Hospital

Nanjing, 210029, China
Renmin Hospital of Wuhan University

Wuhan, 430060, China
Shanghai Chest Hospital

Shanghai, 200000, China
Sir Run Run Shaw Hospital Zhejiang University

Hangzhou, 310016, China
The First Affiliated Hospital of Anhui Medical University

Hefei, 230022, China
The First Affiliated Hospital of Xiamen University

Xiamen, 361003, China
The Third Xiangya Hospital Of Central South University

Changsha, 410013, China
Tianjin Cancer Hospital

Tianjin, 300060, China
Tianjin Medical University General Hospital

Tianjin, 300052, China
Tumor Center,Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, 430023, China
Xuanwu Hospital, Capital Medical University

Beijing, 100053, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.